Sagimet Q1 net loss $10.7M; $175M April financing; Phase 3 acne trial H2 2026

Sagimet Biosciences Inc.

• Net loss $10.7M for Q1 2026 vs $18.2M in Q1 2025; R&D expense $7.0M (down from $15.3M YoY).
• Cash, cash equivalents and marketable securities $104.5M as of March 31, 2026; expects funding through 2028.
• Completed $175M equity financing in April 2026 (29.2M shares at $6.00) to fund acne programs.
• Plans to initiate U.S. Phase 3 trial of denifanstat in moderate-to-severe acne in second half 2026.
• Phase 1 trial of FASN inhibitor TVB-3567 ongoing; Phase 2 planned after completion subject to regulatory consultation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.